Mobile App-Based Remote Management Model for IBD Patient
Inflammatory Bowel Disease (IBD) is a chronic inflammatory condition of the intestines, with its incidence showing a significant year-on-year increase in China. Self-management is becoming increasingly important in the treatment and follow-up of IBD. Numerous studies from Europe and North America have demonstrated that
| Condition(s) | Inflammatory Bowel Diseases |
|---|---|
| Status | Recruiting |
| Phase | NA |
| Study type | Interventional |
| Summary | Inflammatory Bowel Disease (IBD) is a chronic inflammatory condition of the intestines, with its incidence showing a significant year-on-year increase in China. Self-management is becoming increasingly important in the treatment and follow-up of IBD. Numerous studies from Europe and North America have demonstrated that telemedicine can effectively manage disease activity, monitor symptoms, provide education, and improve prognosis. However, its application in China is limited, and there is a lack of high-quality clinical research. This study aims to explore the following objectives: 1. Investigate the level of disease awareness among Chinese IBD patients and their needs related to telemedicine; 2. Develop and preliminarily establish a telemedicine management system and operational process f |
| Who can participate | Inclusion Criteria: 1. Patients will be diagnosed with IBD based on the diagnostic criteria outlined in the "Consensus on Diagnosis and Treatment of Inflammatory Bowel Disease (2018, Beijing)". The diagnosis will be established by combining clinical symptoms, endoscopic examination results, imaging findings, and histological examination results. 2. Participants must be between the ages of 18 and 75 and provide signed informed consent for the project. 3. Within the two years prior to enrollment, medical records must show at least one instance assessed as an inflammatory active phase (Mayo score ≥ 3 or CDAI score ≥ 150). Exclusion Criteria: 1. Participants deemed unable to adhere to the study protocol as determined by the investigators. 2. Individuals with a history of surgical treatment for |
| Ages | 18 Years to 75 Years |
| Sex | All |
| Lead sponsor | Changhai Hospital |
| Locations | Shanghai, Shanghai Municipality, China |
| Start date | 2024-01-01 |
| NCT ID | NCT06512792 |
| Official listing | https://clinicaltrials.gov/study/NCT06512792 |